Compare SCYX & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCYX | MATH |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | Hong Kong |
| Employees | 29 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.0M | 41.9M |
| IPO Year | 2014 | 2016 |
| Metric | SCYX | MATH |
|---|---|---|
| Price | $4.40 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 77.8K | 70.6K |
| Earning Date | 05-06-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | $3.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.84 |
| 52 Week High | $5.62 | $4.10 |
| Indicator | SCYX | MATH |
|---|---|---|
| Relative Strength Index (RSI) | 68.94 | 40.10 |
| Support Level | $0.67 | $0.87 |
| Resistance Level | $5.62 | $1.17 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 70.75 | 12.12 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.